A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Discover the future of Canada's Oncology Market with our comprehensive "Canada Oncology Market Outlook to 2033" report. Covering key segments like Colorectal Cancer and PD-L1 tests, it includes ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Penn State women’s volleyball coach Katie Schumacher-Cawley will receive the Jimmy V Award for Perseverance at Wednesday’s ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

Cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to ...